Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 59.7% | 194.8% | 70.5% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 36.2% | 42.6% | 54.1% | 10% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 1% | -0.1% | -58% | -235.3% |
| Other Income/Exp. Net | -$3 | -$2 | $0 | $2 |
| Pre-Tax Income | -$3 | -$2 | $0 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$2 | $0 | $1 |
| % Margin | -236% | -243.7% | 110.2% | 737% |
| EPS | -0.016 | -0.011 | 0.002 | 0.012 |
| % Growth | -41.2% | -733.3% | -85.1% | – |
| EPS Diluted | -0.016 | -0.011 | 0.002 | 0.012 |
| Weighted Avg Shares Out | 201 | 183 | 182 | 104 |
| Weighted Avg Shares Out Dil | 201 | 183 | 182 | 104 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 1% | -0.1% | -58% | -235.3% |